Skip to main content
. 2023 Jan 27;12(3):987. doi: 10.3390/jcm12030987

Table 2.

Drugs implicated in the induction of DI-SCLE [53,54].

Class Sub-Class Drug
Antihypertensives Thiazide diuretics Hydrochlorothiazide, Hydrochlorothiazide + triamterene, Chlorothiazide
Calcium channel blockers Diltiazem, Verapamil, Nifedipine, Nitrendipine
ACE inhibitors Captopril, Cilazapril, Enalapril, Lisinopril, Ramipril
Beta blockers Acebutolol, Oxprenolol
Proton pump inhibitors Lansoprazole, Esomeprazole, Omeprazole, Pantoprazole
Antifungals Terbinafine, Griseofulvin
Antiepileptics Carbamazepine, Phenytoin
Statins Pravastatin, Simvastatin
Antihistamines Ranitidine, Brompheniramine, Cinnarizine+thiethylperazine
Antibiotics Amoxicillin+clavulanic acid, Ciprofloxacin
NSAIDs Naproxen, Piroxicam
Chemotherapeutics Docetaxel, Paclitaxel, Tamoxifen, Capecitabine, Doxorubicin, Gemcitabine, Masitinib, Mitotane, Palbociclib, Uracil-tegafur,
5-Fluorouracil, Nivolumab, Pembrolizumab
Biologics Anti-TNF Etanercept, Infliximab, Adalimumab, Golimumab, Abatacept
Anti-CD11a Efalizumab
Anti-IL-12/23 Ustekinumab
Anti-IL-17 Secukinumab
Antidepressants Bupropion
Immunomodulators Leflunomide, IFN-α and β
Hormone-altering drugs Leuprorelin, Anastrozole
Others Allopurinol, Ticlopidine, Tiotropium, IVIG